Trials / Conditions / Respiratory Tract Neoplasms

Respiratory Tract Neoplasms

24 registered clinical trials studyying Respiratory Tract Neoplasms — 5 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients NCT07242547	Fundación GECP	Phase 2
Recruiting	PALACE: Cemiplimab Trial According to ctDNA Levels NCT06917573	Fundación GECP	Phase 2
Active Not Recruiting	Small/Middle Tier Cities and County Lung Cancer Quality Improvement Project (QIP) Study NCT06494241	AstraZeneca	—
Active Not Recruiting	Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC NCT06376084	AstraZeneca	—
Recruiting	Early Intervention Strategies for Lung Cancer NCT06988943	The First Affiliated Hospital of Guangzhou Medical University	N/A
Recruiting	A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-S NCT06177925	Nanfang Hospital, Southern Medical University	Phase 2
Recruiting	Real World Registry for Use of the Ion Endoluminal System NCT06004440	Intuitive Surgical	—
Terminated	(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations NCT05241873	Blueprint Medicines Corporation	Phase 1
Terminated	(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC NCT05153408	Blueprint Medicines Corporation	Phase 1
Terminated	(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC NCT04862780	Blueprint Medicines Corporation	Phase 1
Active Not Recruiting	Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO) NCT04776447	Fundación GECP	Phase 2
Terminated	A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic NCT04644315	Hoffmann-La Roche	Phase 2
Unknown	External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patien NCT04697446	Blueprint Medicines Corporation	—
Terminated	A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer NCT04222972	Hoffmann-La Roche	Phase 3
Completed	A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC NCT03134872	Jiangsu HengRui Medicine Co., Ltd.	Phase 3
Unknown	International Lung Screen Trial (ILST) NCT02871856	The University of Queensland	N/A
Completed	Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Can NCT03037385	Hoffmann-La Roche	Phase 1 / Phase 2
Completed	Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors NCT02909452	Syndax Pharmaceuticals	Phase 1
Completed	Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors NCT02897778	Syndax Pharmaceuticals	Phase 1
Unknown	Alberta Lung Cancer Screening Program NCT02431962	University of Calgary	N/A
Unknown	The EPIC Trial The Elderly Patient Individualized Chemotherapy Trial NCT03402048	University of Turin, Italy	Phase 3
Completed	A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer NCT01039948	AVEO Pharmaceuticals, Inc.	Phase 1 / Phase 2
Completed	High Dose Somatostatin Analogues in Neuroendocrine Tumors NCT00990535	Federico II University	Phase 2
No Longer Available	Expanded Access Program of Taletrectinib in Patients With Advanced or Metastatic ROS1-Positive NSCLC NCT06841874	Nuvation Bio Inc.	—